Tearsheet

TG Therapeutics (TGTX)

Market Price (10/31/2025): $34.06 | Market Cap: $5.0 Bil
Sector: Health Care | Industry: Biotechnology

TG Therapeutics (TGTX)

Market Price (10/31/2025): $34.06
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31%	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16%	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 51x, P/EPrice/Earnings or Price/(Net Income) is 83x
1			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
2			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3%
3			Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15

0	Strong revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is 31%
1	Meaningful short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16%
2	Expensive valuation multiples P/EBITPrice/EBIT or Price/(Operating Income) ratio is 51x, P/EPrice/Earnings or Price/(Net Income) is 83x
3	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -13%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -13%
4	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -3.3%
5	Significant short interest Short Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 15

Market Valuation & Key Metrics

Valuation
Key Metrics

	10/31/25	2024	2023	2022	2021
Share Price CYE	$34.06	$30.10	$17.08	$11.83	$19.00
Market Cap CYE ($ Bil)	5.0	4.4	2.4	1.6	2.5
Total Debt ($ Bil)	0.3	0.3	0.1	0.1	0.1
Total Cash ($ Bil)	0.3	0.3	0.2	0.2	0.3
Enterprise Value ($ Bil)	5.0	4.7	2.5	1.7	2.6
Valuation Ratios
P/S TTM	11.0	13.3	10.4	575.2	375.6
P/EBIT TTM	51.3	88.2	94.4	-7.5	-7.3
P/E TTM	82.7	187.1	191.3	-7.2	-7.2
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0	4.5	7.3
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4	-1.3	-2.7
P/E TTM (Sector)	-2.0	-1.5	-1.5	-1.3	-2.8

	10/31/25	2024	2023
Share Price CYE	$34.06	$30.10	$17.08
Market Cap CYE ($ Bil)	5.0	4.4	2.4
Total Debt ($ Bil)	0.3	0.3	0.1
Total Cash ($ Bil)	0.3	0.3	0.2
Enterprise Value ($ Bil)	5.0	4.7	2.5
Valuation Ratios
P/S TTM	11.0	13.3	10.4
P/EBIT TTM	51.3	88.2	94.4
P/E TTM	82.7	187.1	191.3
Sector Ratios
P/S TTM (Sector)	4.0	3.5	4.0
P/EBIT TTM (Sector)	-1.6	-1.3	-1.4
P/E TTM (Sector)	-2.0	-1.5	-1.5

	TGTX	S&P 500
REVENUE GROWTH	VERY GOOD
Rev LTM ($ Bil)	0.5
Rev Chg Q	92.1%	6.5%
Rev Chg LTM	31.0%	5.4%
Rev Chg 3Y Avg	539.4%	5.3%
PROFITABILITY	POOR
Op Inc LTM ($ Bil)	0.1
CFO LTM ($ Bil)	-0.1
Net Inc LTM ($ Bil)	0.1
Op Mgn LTM	18.9%	18.7%
CFO/Rev LTM	-13.0%	20.3%
Net Inc Mgn	13.3%	12.7%
VALUATION	VERY HIGH
P/S	11.0	3.2
P/CFO	-84.5	15.3
P/FCF	-84.4	20.3
P/E	82.7	23.6
STABILITY	VERY GOOD
Debt/Equity	0.05	0.21
Cash/Assets	0.36	0.07

TGTX Stock

Return (1M):

Factor Drivers of Stock Movement

The -4.2% change in TGTX stock from 7/31/2025 to 10/30/2025 was primarily driven by a -37.9% change in the company's P/E Multiple.

	7312025	10302025	Change
Stock Price ($)	35.50	34.02	-4.17%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	386.39	454.07	17.52%
Net Income Margin (%)	10.13%	13.31%	31.41%
P/E Multiple	133.00	82.57	-37.92%
Shares Outstanding (Mil)	146.68	146.74	-0.04%
Cumulative Contribution			-4.17%

LTM = Last Twelve Months as of date shown

The -25.0% change in TGTX stock from 5/1/2025 to 10/30/2025 was primarily driven by a -70.7% change in the company's P/E Multiple.

	5012025	10302025	Change
Stock Price ($)	45.37	34.02	-25.02%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	329.00	454.07	38.01%
Net Income Margin (%)	7.11%	13.31%	87.34%
P/E Multiple	281.81	82.57	-70.70%
Shares Outstanding (Mil)	145.24	146.74	-1.03%
Cumulative Contribution			-25.02%

LTM = Last Twelve Months as of date shown

The 35.4% change in TGTX stock from 10/30/2024 to 10/30/2025 was primarily driven by a 117.2% change in the company's P/E Multiple.

	10302024	10302025	Change
Stock Price ($)	25.13	34.02	35.38%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	346.73	454.07	30.96%
Net Income Margin (%)	27.60%	13.31%	-51.75%
P/E Multiple	38.01	82.57	117.24%
Shares Outstanding (Mil)	144.73	146.74	-1.39%
Cumulative Contribution			35.35%

LTM = Last Twelve Months as of date shown

The 484.5% change in TGTX stock from 10/31/2022 to 10/30/2025 was primarily driven by a 6423.0% change in the company's Total Revenues ($ Mil).

	10312022	10302025	Change
Stock Price ($)	5.82	34.02	484.54%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	6.96	454.07	6423.03%
P/S Multiple	112.69	10.99	-90.24%
Shares Outstanding (Mil)	134.78	146.74	-8.87%
Cumulative Contribution			479.93%

LTM = Last Twelve Months as of date shown

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
TGTX Return	369%	-63%	-38%	44%	76%	13%	200%
Peers Return	4%	-26%	-28%	13%	30%	-4%	-21%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	110%
Monthly Win Rates [3]
TGTX Win Rate	75%	33%	33%	50%	58%	56%
Peers Win Rate	28%	17%	25%	36%	35%	60%
S&P 500 Win Rate	58%	75%	42%	67%	75%	67%
Max Drawdowns [4]
TGTX Max Drawdown	-36%	-71%	-80%	-44%	-24%	-12%
Peers Max Drawdown	-43%	-30%	-33%	-27%	-42%	-41%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: KURA, CRVS, APM, BBOT, GDTC. See TGTX Returns vs. Peers.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique Key	Event	TGTX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-93.1%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	1351.9%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-55.3%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	123.9%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	48 days	148 days
2018 Correction	2018 Correction
2018 Correction% Loss	% Loss	-79.5%	-19.8%
2018 Correction% Gain to Breakeven	% Gain to Breakeven	388.4%	24.7%
2018 CorrectionTime to Breakeven	Time to Breakeven	499 days	120 days
2008 Global Financial Crisis	2008 Global Financial Crisis
2008 Global Financial Crisis% Loss	% Loss	-99.5%	-56.8%
2008 Global Financial Crisis% Gain to Breakeven	% Gain to Breakeven	18233.3%	131.3%
2008 Global Financial CrisisTime to Breakeven	Time to Breakeven	Not Fully Recovered days	1480 days

Compare to KURA, CRVS, APM, BBOT, GDTC

In The Past

TG Therapeutics's stock fell -93.1% during the 2022 Inflation Shock from a high on 2/5/2021. A -93.1% loss requires a 1351.9% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About TG Therapeutics (TGTX)

Business Description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Better Bets than TG Therapeutics (TGTX)

	TGTX	Better Performance than TGTX
Metric	Value	Industry (Biotechnology)
Rev Chg LTM	31.0%	BBIO (62.5%), MDGL (3422.0%), HALO (35.0%), CYTK (2635.7%), RYTM (53.5%)
Rev Chg 3Y Avg	539.4%	BBIO (727.6%), CYTK (824.6%), AXSM (699.5%), ARWR (908.8%), ARQT (2325.4%)
Op Mgn LTM	18.9%	ABBV (23.5%), AMGN (23.5%), GILD (37.4%), REGN (26.7%), BIIB (24.8%)
CFO/Rev LTM	-13.0%	ABBV (33.1%), AMGN (34.4%), GILD (34.2%), VRTX (33.7%), REGN (35.6%)
FCF/Rev LTM	-13.0%	ABBV (31.3%), AMGN (30.4%), GILD (32.5%), VRTX (30.6%), REGN (27.2%)
Total Yield	1.2%	ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)

	TGTX	Better Performance than TGTX
Metric	Value	Sector (Health Care)
Rev Chg LTM	31.0%	LLY (36.8%), NTRA (44.4%), TEM (59.8%), BBIO (62.5%), HIMS (88.7%)
Rev Chg 3Y Avg	539.4%	BBIO (727.6%), CYTK (824.6%), AXSM (699.5%), ARWR (908.8%), ARQT (2325.4%)
Op Mgn LTM	18.9%	LLY (43.0%), JNJ (26.2%), ABBV (23.5%), MRK (31.2%), ISRG (29.3%)
CFO/Rev LTM	-13.0%	LLY (20.5%), JNJ (26.3%), ABBV (33.1%), UNH (4.8%), ABT (20.8%)
FCF/Rev LTM	-13.0%	LLY (-0.1%), JNJ (20.3%), ABBV (31.3%), UNH (4.0%), ABT (15.8%)
Total Yield	1.2%	LLY (2.5%), JNJ (8.2%), ABBV (3.7%), UNH (8.1%), ABT (8.3%)

	TGTX	Better Performance than TGTX
Metric	Value	All Other Sectors
Rev Chg LTM	31.0%	NVDA (71.6%), PLTR (38.8%), MU (48.9%), APP (48.2%), APH (47.4%)
Rev Chg 3Y Avg	539.4%	QXO (1115.2%), UEC (10082.6%), PFLT (12481.5%), URG (7785.9%), GEVO (729.7%)
Op Mgn LTM	18.9%	NVDA (58.1%), AAPL (31.9%), MSFT (46.3%), GOOGL (32.2%), AVGO (39.0%)
CFO/Rev LTM	-13.0%	NVDA (46.6%), AAPL (26.6%), MSFT (50.0%), GOOGL (39.3%), AMZN (18.1%)
FCF/Rev LTM	-13.0%	NVDA (43.6%), AAPL (23.5%), MSFT (26.6%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	1.2%	NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)

		Best Bets In Health Care Sector
	TGTX	RPRX	HALO	CPRX	BMY	LNTH	PBH	BIIB	PFE	EW	ILMN
What You Pay
P/E	82.6	15.3	14.1	12.3	15.4	14.0	14.0	13.6	12.8	11.8	12.4
P/EBIT	51.2	8.1	11.0	10.5	9.3	9.6	9.0	10.1	10.3	29.2	10.3
What You Get
Rev Chg Q	92.1%	7.7%	40.8%	19.4%	2.8%	-4.1%	-6.6%	2.8%	10.3%	11.9%	-4.8%
Rev Chg LTM	31.0%	3.0%	35.0%	28.5%	1.3%	5.7%	0.6%	4.8%	13.5%	9.1%	-3.3%
Rev Chg 3Y Avg	539.4%	0.8%	35.5%	49.9%	1.0%	34.3%	0.8%	-0.9%	-12.4%	3.0%	-3.0%
FCF/Rev 3Y Avg	-220.0%	113.4%	43.4%	38.9%	29.0%	26.1%	21.6%	17.0%	13.8%	11.9%	9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic	Date
0	DASHBOARDS
1	TG Therapeutics Earnings Notes
2	TG Therapeutics Stock Fell 6.5% in a Month, What Now?	Return
3	TGTX's 28% Decline in a Month Brings Valuations Into Focus - Is STOK a Better Deal?	Counter-Intuitive Comparisons
4	TGTX Dip Buy Analysis
5	TG Therapeutics Total Shareholder Return (TSR): 76.2% in 2024 and 16.6% 3-yr compounded annual returns (above peer average)
6	TG Therapeutics Market Price	Market Price
7	TG Therapeutics (TGTX) Operating Cash Flow Comparison	Financials
8	TG Therapeutics (TGTX) Net Income Comparison	Financials
9	TG Therapeutics (TGTX) Operating Income Comparison	Financials
10	TG Therapeutics (TGTX) Revenue Comparison	Financials
11	ARTICLES
12	Market Movers \| Winners: COMM, SCS, IDXX \| Losers: REPL, TGTX, ON		August 5th, 2025
13	Down 57% In A Month, Is There More Pain For TG Therapeutics Stock?		January 28th, 2022
14	Is A Rise Imminent For TG Therapeutics Stock After A Large 50% Fall In A Month?		December 8th, 2021
15	What’s Next For TG Therapeutics Stock After The Recent 25% Fall?		May 20th, 2021

	Title
0	DASHBOARDS
1	Market Movers \| Winners: COMM, SCS, IDXX \| Losers: REPL, TGTX, ON
2	Down 57% In A Month, Is There More Pain For TG Therapeutics Stock?
3	Is A Rise Imminent For TG Therapeutics Stock After A Large 50% Fall In A Month?
4	What’s Next For TG Therapeutics Stock After The Recent 25% Fall?
5	ARTICLES
6	TG Therapeutics Earnings Notes
7	TG Therapeutics Stock Fell 6.5% in a Month, What Now?
8	TGTX's 28% Decline in a Month Brings Valuations Into Focus - Is STOK a Better Deal?
9	TGTX Dip Buy Analysis
10	TG Therapeutics Total Shareholder Return (TSR): 76.2% in 2024 and 16.6% 3-yr compounded annual returns (above peer average)
11	TG Therapeutics Market Price
12	TG Therapeutics (TGTX) Operating Cash Flow Comparison
13	TG Therapeutics (TGTX) Net Income Comparison
14	TG Therapeutics (TGTX) Operating Income Comparison
15	TG Therapeutics (TGTX) Revenue Comparison

Trade Ideas

Select past ideas related to TGTX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy	09302025	ADMA	ADMA Biologics	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	4.2%	4.2%	-4.6%
REGN_9302025_Dip_Buyer_ValueBuy	09302025	REGN	Regeneron Pharmaceuticals	Dip Buy	DB \| P/E OPMDip Buy with Low PE and High Margin Buying dips for companies with tame PE and meaningfully high operating margin	16.3%	16.3%	-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	09262025	HAE	Haemonetics	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	3.8%	3.8%	-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper	09192025	WAT	Waters	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	14.0%	14.0%	-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper	09052025	ISRG	Intuitive Surgical	Monopoly	MY \| Getting CheaperMonopoly-Like with P/S Decline Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple	13.5%	13.5%	-8.0%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

1 Month Top Gainers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PRAX	Praxis Precision Medicines	279.1%	161.2%
2	INBX	Inhibrx Biosciences	131.0%	409.8%
3	PUMP	ProPetro	99.6%	16.2%
4	DYN	Dyne Therapeutics	88.4%	-0.0%
5	VICR	Vicor	85.4%	89.2%
6	CELC	Celcuity	74.6%	503.2%
7	GLUE	Monte Rosa Therapeutics	73.5%	87.5%
8	NVTS	Navitas Semiconductor	72.1%	251.8%
9	LUMN	Lumen Technologies	70.3%	94.7%
10	BALY	Ballys	63.4%	4.1%

1 Month Top Losers

#	Ticker	Company	1M Rtn	YTD Rtn
1	PMI	Picard Medical	-62.9%	5106.3%
2	LRN	Stride	-53.8%	-35.8%
3	FMC	FMC	-51.0%	-66.6%
4	FI	Fiserv	-48.3%	-68.3%
5	NFE	New Fortress Energy	-43.6%	-91.9%
6	VG	Venture Global	-41.7%
7	OGN	Organon	-40.2%	-55.0%
8	VRNS	Varonis Systems	-39.5%	-21.2%
9	ITGR	Integer	-38.5%	-52.2%
10	LENZ	LENZ Therapeutics	-37.9%	5.5%

Recent Active Movers

1 Day Top Gainers

#	Ticker	Company	1D Rtn	YTD Rtn
1	GH	Guardant Health	27.9%	202.5%
2	GCI	Gannett	27.7%	3.8%
3	FORM	FormFactor	24.2%	34.7%
4	VIAV	Viavi Solutions	22.3%	69.3%
5	GSAT	Globalstar	22.2%	63.5%
6	MTSR	Metsera	22.1%	63729900.0%
7	PRM	Perimeter Solutions	21.1%	102.3%
8	CHRW	C.H. Robinson Worldwide	19.7%	52.6%
9	INSM	Insmed	16.3%	181.3%
10	CAH	Cardinal Health	15.4%	62.8%

1 Day Top Losers

#	Ticker	Company	1D Rtn	YTD Rtn
1	FMC	FMC	-46.5%	-66.6%
2	APLS	Apellis Pharmaceuticals	-31.0%	-35.0%
3	THRY	Thryv	-30.2%	-44.8%
4	SFM	Sprouts Farmers Market	-26.1%	-39.2%
5	IART	Integra Lifesciences	-23.5%	-47.9%
6	ITRI	Itron	-21.1%	0.4%
7	WOLF	Wolfspeed	-18.2%
8	CMG	Chipotle Mexican Grill	-18.2%	-46.1%
9	CI	Cigna	-17.4%	-9.2%
10	EME	EMCOR	-16.6%	43.0%

1 Week Top Gainers

#	Ticker	Company	1W Rtn	YTD Rtn
1	INBX	Inhibrx Biosciences	176.8%	409.8%
2	PUMP	ProPetro	71.2%	16.2%
3	RNA	Avidity Biosciences	43.5%	139.6%
4	DYN	Dyne Therapeutics	42.8%	-0.0%
5	GCI	Gannett	39.3%	3.8%
6	FORM	FormFactor	38.3%	34.7%
7	MBX	MBX Biosciences	35.1%	18.2%
8	BBNX	Beta Bionics	33.8%
9	GH	Guardant Health	33.3%	202.5%
10	LUMN	Lumen Technologies	32.7%	94.7%

1 Week Top Losers

#	Ticker	Company	1W Rtn	YTD Rtn
1	PMI	Picard Medical	-75.2%	5106.3%
2	LRN	Stride	-56.1%	-35.8%
3	NTLA	Intellia Therapeutics	-52.6%	5.2%
4	FMC	FMC	-48.7%	-66.6%
5	FI	Fiserv	-47.4%	-68.3%
6	VRNS	Varonis Systems	-43.8%	-21.2%
7	THRY	Thryv	-33.4%	-44.8%
8	NFE	New Fortress Energy	-30.5%	-91.9%
9	AKBA	Akebia Therapeutics	-29.5%	10.5%
10	UAMY	United States Antimony	-28.9%	371.2%

Peer Comparisons for TG Therapeutics

Financials

	TGTX	KURA	CRVS	APM	BBOT	GDTC	Median
Name	TG Thera.	Kura Onc.	Corvus P.	Aptorum	BridgeBi.	CytoMed .
Mkt Price	34.02	10.44	7.76	1.47	12.00	2.15	9.10
Mkt Cap	5.0	0.9	0.6	-	-	-	0.9
Rev LTM	454	83	0	-	0	-	42
Op Inc LTM	86	-220	-36	-	-93	-	-64
FCF LTM	-59	123	-29	-	-60	-	-44
FCF 3Y Avg	-51	-47	-26	-	-	-	-47
CFO LTM	-59	125	-29	-	-60	-	-44
CFO 3Y Avg	-51	-46	-26	-	-	-	-46

Growth & Margins

	TGTX	KURA	CRVS	APM	BBOT	GDTC	Median
Name	TG Thera.	Kura Onc.	Corvus P.	Aptorum	BridgeBi.	CytoMed .
Rev Chg LTM	31.0%	-	-	-	-	-	31.0%
Rev Chg 3Y Avg	539.4%	-	-	-	-	-	539.4%
Rev Chg Q	92.1%	-	-	-	-	-	92.1%
QoQ Delta Rev Chg LTM	17.5%	22.5%	-	-	-	-	20.0%
Op Mgn LTM	18.9%	-263.8%	-	-	-	-	-122.5%
Op Mgn 3Y Avg	-253.0%	-	-	-	-	-	-253.0%
QoQ Delta Op Mgn LTM	3.4%	35.4%	-	-	-	-	19.4%
CFO/Rev LTM	-13.0%	150.1%	-	-	-	-	68.5%
CFO/Rev 3Y Avg	-219.9%	-	-	-	-	-	-219.9%
FCF/Rev LTM	-13.0%	147.5%	-	-	-	-	67.2%
FCF/Rev 3Y Avg	-220.0%	-	-	-	-	-	-220.0%

Valuation

	TGTX	KURA	CRVS	APM	BBOT	GDTC	Median
Name	TG Thera.	Kura Onc.	Corvus P.	Aptorum	BridgeBi.	CytoMed .
Mkt Cap	5.0	0.9	0.6	-	-	-	0.9
P/S	11.0	11.0	-	-	-	-	11.0
P/EBIT	51.2	-4.7	-17.0	-	-	-	-4.7
P/E	82.6	-4.6	-13.4	-	-	-	-4.6
P/CFO	-84.4	7.3	-20.9	-	-	-	-20.9
Total Yield	1.2%	-21.6%	-7.5%	-	-	-	-7.5%
Dividend Yield	0.0%	0.0%	0.0%	-	-	-	0.0%
FCF Yield 3Y Avg	-1.0%	0.3%	-18.2%	-	-	-	-1.0%
D/E	0.1	0.0	0.0	-	-	-	0.0
Net D/E	0.0	-0.7	-0.1	-	-	-	-0.1

Returns

	TGTX	KURA	CRVS	APM	BBOT	GDTC	Median
Name	TG Thera.	Kura Onc.	Corvus P.	Aptorum	BridgeBi.	CytoMed .
1M Rtn	-5.8%	18.0%	5.3%	-27.2%	3.6%	8.0%	4.5%
3M Rtn	-4.2%	72.6%	86.1%	-5.2%	-	14.4%	14.4%
6M Rtn	-25.0%	60.9%	120.5%	59.8%	-	-6.5%	59.8%
12M Rtn	35.4%	-38.5%	-11.8%	5.0%	-	-3.4%	-3.4%
3Y Rtn	484.5%	-32.7%	795.0%	-76.8%	-	-	225.9%
1M Excs Rtn	-8.6%	11.8%	5.2%	-34.2%	-1.9%	5.3%	1.7%
3M Excs Rtn	-12.2%	64.1%	79.9%	-2.1%	-	8.1%	8.1%
6M Excs Rtn	-46.8%	39.1%	98.7%	38.0%	-	-28.3%	38.0%
12M Excs Rtn	22.6%	-58.3%	-27.3%	-17.8%	-	-33.2%	-27.3%
3Y Excs Rtn	455.6%	-113.6%	687.4%	-151.9%	-	-	171.0%

Comparison Analyses

	Title
0	TG Therapeutics vs Viavi Solutions: Similar Market Cap; Which Stock Is A Better Bet?
1	TG Therapeutics vs Fluor: Similar Market Cap; Which Stock Is A Better Bet?
2	TG Therapeutics vs Cogent Communications Group: Similar Market Cap; Which Stock Is A Better Bet?
3	TG Therapeutics vs Balchem: Similar Market Cap; Which Stock Is A Better Bet?
4	TG Therapeutics vs Alliance Data Systems: Similar Market Cap; Which Stock Is A Better Bet?
5	TG Therapeutics vs Simpson Manufacturing: Similar Market Cap; Which Stock Is A Better Bet?
6	TG Therapeutics vs Kulicke and Soffa Industries: Similar Market Cap; Which Stock Is A Better Bet?
7	TG Therapeutics vs Tripadvisor: Similar Market Cap; Which Stock Is A Better Bet?

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/8/2025	3/3/2025	2/29/2024	3/1/2023	3/1/2022	3/1/2021	3/2/2020
Key Financials
Total Revenue	454	329	234	3	7	0	0
EBITDA	98	50	26	-213	-342	-273	-167
Operating Income	86	42	21	-218	-345	-274	-169
Net Income	60	23	13	-224	-348	-279	-173
EPS	0.41	0.16	0.09	-1.65	-2.63	-2.42	-1.96
Growth Rates
Total Revenue Growth	31.0%	40.8%	8290.0%	-58.4%	4300.7%	0.0%	0.0%
EBITDA Growth	-10.0%	91.2%	112.2%	37.7%	-25.4%	-63.0%	2.9%
Operating Income Growth	-15.7%	103.2%	109.5%	36.7%	-26.0%	-61.8%	3.1%
Net Income Growth	-36.8%	84.5%	105.7%	35.7%	-24.6%	-61.6%	0.4%
Margins
EBITDA Margin	21.5%	15.2%	11.2%	-7651.9%	-5112.4%	-179393.4%	-110067.1%
Operating Income Margin	18.9%	12.7%	8.8%	-7839.0%	-5154.3%	-179996.1%	-111220.4%
Net Income Margin	13.3%	7.1%	5.4%	-8036.3%	-5204.1%	-183803.3%	-113730.9%
Cash & Debt
Total Cash	252	311	218	162	315	605	140
Total Debt	254	254	111	83	79	42	41
Net Debt / (Cash)	2	-57	-107	-79	-236	-563	-100
Cash Flows
Net Cash from Operations	-59	-41	-31	-176	-296	-215	-133
Free Cash from Operations	-59	-41	-31	-176	-296	-215	-133
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	22	9	-0	-0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/8/2025	5/9/2025	3/3/2025	11/7/2024	8/9/2024	5/6/2024	2/29/2024	11/6/2023	8/4/2023	5/8/2023	3/1/2023	11/9/2022
Key Financials Quarterly
Total Revenue	141	121	108	84	73	63	44	166	16	8	0	0
Ebitda	38	12	33	15	11	-8	-12	118	-44	-36	-75	-34
Operating Income	35	9	30	12	9	-9	-12	115	-45	-37	-78	-35
Net Income	28	5	23	4	7	-11	-14	114	-48	-39	-78	-36
EPS	0.19	0.03	0.16	0.03	0.05	-0.07	-0.10	0.80	-0.34	-0.28	-0.39	-0.26
Key Financials TTM
Total Revenue TTM	454	386	329	265	347	289	234	190	24	9	3	5
Ebitda TTM	98	71	50	6	109	54	26	-38	-190	-183	-213	-230
Operating Income TTM	86	60	42	-1	102	48	21	-44	-194	-188	-218	-234
Net Income TTM	60	39	23	-14	96	41	13	-51	-201	-194	-224	-239
Growth Rates Quarterly
Total Revenue Growth	92.1%	90.4%	146.0%	-49.4%	357.0%	713.5%	54863.8%	176298.9%	2606.1%	287.1%	-96.6%	-95.4%
EBITDA Growth	255.6%	247.8%	383.2%	-87.1%	124.1%	77.1%	84.8%	446.0%	-17.5%	45.2%	18.1%	59.7%
Operating Income Growth	295.2%	193.0%	339.9%	-89.2%	119.7%	74.9%	83.9%	428.3%	-14.7%	44.7%	16.6%	58.9%
Net Income Growth	309.8%	147.3%	261.8%	-96.6%	114.4%	72.7%	81.6%	418.1%	-17.5%	43.2%	15.9%	58.2%
Margins Quarterly
EBITDA Margin	26.7%	10.2%	30.1%	18.1%	14.4%	-13.1%	-26.2%	71.0%	-273.1%	-464.8%	-94353.8%	-36213.8%
Operating Income Margin	24.7%	7.1%	27.7%	14.8%	12.0%	-14.6%	-28.4%	69.2%	-277.9%	-474.1%	-96923.8%	-37194.7%
Net Income Margin	20.0%	4.2%	21.6%	4.6%	9.4%	-16.9%	-32.8%	68.7%	-296.2%	-502.8%	-98088.8%	-38104.3%
Cash & Debt
Total Cash	252	276	311	341	217	210	218	229	145	140	162	176
Total Debt	254	254	254	254	113	112	111	110	109	108	83	82
Net Debt / (Cash)	2	-23	-57	-87	-105	-98	-107	-119	-36	-32	-79	-94
Cash Flows Quarterly
FCF from Operations	7	-29	-26	-12	6	-8	-13	84	-42	-60	-24	-34
Cash Flows TTM
FCF from Operations TTM	-59	-61	-41	-28	68	20	-31	-42	-160	-167	-176	-239
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	7	6	7	2	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	7.3%	1.9%	6.5%	2.7%	2.2%	-2.3%	-3.1%	29.7%	-11.0%	-9.5%	-20.6%	-9.4%
Return on Invested Capital (ROIC) TTM
ROIC TTM	4.5%	3.3%	2.3%	-0.0%	6.2%	3.0%	1.2%	-2.9%	-12.0%	-12.1%	-14.5%	-15.8%

Segment Financials

Revenue by Segment

$ Mil	2024	2023	2022	2021	2020
License, milestone, royalty and other revenue	142	0
BRIUMVI	92	0
UKONIQ	0	3
License Revenue			0
Other Revenue			0
Product revenue, net			7
Single Segment				0	0
Total	234	3	7	0	0

Price Behavior

Price Behavior

Market Price	$34.02
Market Cap ($ Bil)	5.0
First Trading Date	12/29/2006
Distance from 52W High	-25.2%
	50 Days	200 Days
DMA Price	$33.33	$34.82
DMA Trend	up	up
Distance from DMA	2.1%	-2.3%
	3M	1YR
Volatility	49.6%	58.1%
Downside Capture	58.40	137.94
Upside Capture	17.26	145.35
Correlation (SPY)	2.1%	23.1%

TGTX Betas & Captures as of 9/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	1.63	-0.88	-0.11	0.48	0.68	1.67
Up Beta	3.51	-4.75	-3.42	0.08	0.16	1.88
Down Beta	-1.75	0.35	-0.21	0.55	0.39	1.31
Up Capture	355%	13%	85%	72%	214%	1266%
Bmk +ve Days	13	23	35	74	144	420
Stock +ve Days	13	24	32	66	126	372
Down Capture	-53%	-0%	143%	125%	119%	108%
Bmk -ve Days	8	19	29	52	107	330
Stock -ve Days	8	18	31	59	123	376

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date	10152025
Short Interest: Shares Quantity	23,810,220
Short Interest: % Change Since 9302025	0.9%
Average Daily Volume	1,545,477
Days-to-Cover Short Interest	15.41
Basic Shares Quantity	146,739,833
Short % of Basic Shares	16.2%

Returns Analyses

	Title
0	TG Therapeutics Stock Fell 6.5% in a Month, What Now?
1	TG Therapeutics Stock Return Comparison
2	[10/6/2021] TG Therapeutics (TGTX) Stock Price Forecast: AI Forecasts TGTX Stock Price To Be Around $64.8 In A Month (Up 108%)
3	TG Therapeutics Total Shareholder Return (TSR): -37.7% in 2022 and 2.1% 3-yr returns (below peer average)
4	Biotechnology Industry Return: 38% YTD Return vs 17% For S&P 500

Earnings Returns History

Expand for More

	Forward Returns
Earnings Date	1D Returns	5D Returns	21D Returns
8/4/2025	-18.0%	-23.7%	-15.1%
3/3/2025	14.4%	27.8%	31.0%
11/4/2024	-9.4%	7.1%	24.1%
8/6/2024	19.6%	20.0%	28.3%
2/28/2024	26.7%	30.0%	11.9%
11/1/2023	30.9%	40.1%	65.7%
8/1/2023	-49.3%	-51.2%	-49.4%
2/28/2023	0.6%	9.7%	-8.0%
...
SUMMARY STATS
# Positive	10	12	11
# Negative	9	7	8
Median Positive	17.0%	14.9%	14.8%
Median Negative	-9.4%	-23.7%	-19.4%
Max Positive	63.4%	64.0%	65.7%
Max Negative	-49.3%	-51.2%	-52.5%

	Forward Returns
8/4/2025	-18.0%	-23.7%	-15.1%
3/3/2025	14.4%	27.8%	31.0%
11/4/2024	-9.4%	7.1%	24.1%
8/6/2024	19.6%	20.0%	28.3%
2/28/2024	26.7%	30.0%	11.9%
11/1/2023	30.9%	40.1%	65.7%
8/1/2023	-49.3%	-51.2%	-49.4%
2/28/2023	0.6%	9.7%	-8.0%
11/10/2022	63.4%	64.0%	45.7%
8/8/2022	20.7%	33.4%	-6.6%
3/1/2022	4.3%	-12.2%	7.0%
11/4/2021	5.9%	1.0%	-52.5%
8/2/2021	-21.6%	-32.8%	-23.7%
3/2/2021	-0.3%	-7.3%	0.6%
11/9/2020	-2.5%	2.2%	2.6%
8/10/2020	-11.0%	2.6%	14.1%
3/3/2020	-3.4%	-26.6%	-29.7%
11/12/2019	-2.8%	1.9%	14.8%
8/9/2019	4.2%	-5.1%	-6.8%
SUMMARY STATS
# Positive	10	12	11
# Negative	9	7	8
Median Positive	17.0%	14.9%	14.8%
Median Negative	-9.4%	-23.7%	-19.4%
Max Positive	63.4%	64.0%	65.7%
Max Negative	-49.3%	-51.2%	-52.5%

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8082025	10-Q 6/30/2025
3312025	5092025	10-Q 3/31/2025
12312024	3032025	10-K 12/31/2024
9302024	11072024	10-Q 9/30/2024
6302024	8092024	10-Q 6/30/2024
3312024	5062024	10-Q 3/31/2024
12312023	2292024	10-K 12/31/2023
9302023	11062023	null 9/30/2023
6302023	8042023	10-Q 6/30/2023
3312023	5082023	10-Q 3/31/2023
12312022	3012023	10-K 12/31/2022
9302022	11092022	10-Q 9/30/2022
6302022	8092022	10-Q 6/30/2022
3312022	5102022	10-Q 3/31/2022
12312021	3012022	10-K 12/31/2021
9302021	11082021	10-Q 9/30/2021

Insider Activity

Expand for More

	Owner	Title	Filing Date	Action	Price	Shares	Transacted Value	Value of Held Shares	Form
0	Power Sean A	CFO	1072025	Sell	30.29	11,337	343,443	20,316,126	Form
1	Lonial Sagar		11122024	Sell	30.44	5,000	152,200	3,049,936	Form
2	Charney Laurence N		11122024	Sell	30.20	25,000	754,875	6,415,803	Form
3	Echelard Yann		11072024	Sell	24.48	20,000	489,600	5,485,919	Form

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

TG Therapeutics (TGTX)

Market Price (10/31/2025): $34.06 | Market Cap: $5.0 BilSector: Health Care | Industry: Biotechnology

TG Therapeutics (TGTX)

Market Price (10/31/2025): $34.06Market Cap: $5.0 BilSector: Health CareIndustry: Biotechnology

Market Valuation & Key Metrics

TGTX Stock

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About TG Therapeutics (TGTX)

Interactive Breakdown

Better Bets than TG Therapeutics (TGTX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for TG Therapeutics

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (10/31/2025): $34.06 | Market Cap: $5.0 Bil
Sector: Health Care | Industry: Biotechnology

Market Price (10/31/2025): $34.06
Market Cap: $5.0 Bil
Sector: Health Care
Industry: Biotechnology